Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

Adenocarcinoma of the Prostate Clinical Trial

Official title:

Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02163317
• Other study ID #: CASE11813
• Secondary ID: NCI-2014-01170
• Status: Completed
• Phase: N/A
• Start date: February 16, 2016
• Est. completion date: July 28, 2021

Study information

• Verified date: May 2024
• Source: Case Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot clinical trial studies magnetic resonance (MRI)-guided focal stereotactic radiosurgery (SRS) in treating patients with low- or intermediate-risk localized prostate cancer. Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

Description:

PRIMARY OBJECTIVES: I. Evaluate the correlation of histopathology findings in comparison to regions of the prostate reported to be suspicious for harboring tumor burden on multiparametric MRI report/s. II. Demonstration of the dosimetric and radiobiological advantages of focal stereotactic body radiation therapy (SBRT) versus whole-gland radiation therapy. III. Evaluation of clinical outcomes in focal SBRT for localized prostate cancer. OUTLINE: Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months. After completion of study treatment, patients are followed up every 3 months for up to 24 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: July 28, 2021
• Est. primary completion date: July 28, 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have a histologically confirmed diagnosis of adenocarcinoma of the prostate
• Patient must have a history/physical examination with digital rectal examination of the prostate within 90 days prior to screening
• Eastern Cooperative Oncology Group (ECOG) performance status must be level 0 or 1 within 60 days prior to registration
• Patient must have a histological evaluation of the prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason scores = 7(3+4)
• Serum creatinine = 1.5 times upper limit of institutional normal (normal: = 1.17 mL/min/1.73 m^2)
• Clinical stage a = T1-T2a (American Joint Committee on Cancer [AJCC] 7th edition)
• Prostate specific antigen (PSA) = 10 ng/mL within 90 days prior to registration; PSA should not be obtained within 10 days after prostate biopsy
• Subjects must have the ability to understand and the willingness to sign a written informed consent document
• Patient willing and able to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire (baseline, 6, 12 and 24 months post end of radiation therapy)
• Patients must be able to undergo an MRI with contrast
• Bone scan completed within 90 days

Exclusion Criteria:

• Evidence of distant metastases
• Regional lymph node involvement
• Previous radical surgery (prostatectomy), cryosurgery, or high intensity focused ultrasound (HIFU) for prostate cancer
• Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
• Previous hormonal therapy, such as luteinizing hormone-releasing hormone (LHRH) agonists (e.g., goserelin, leuprolide) or LHRH antagonists (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., diethylstilbestrol [DES]), or surgical castration (orchiectomy)
• Use of finasteride within 30 days prior to registration; PSA should not be obtained prior to 30 days after stopping finasteride
• Use of dutasteride within 90 days prior to registration; PSA should not be obtained prior to 90 days after stopping dutasteride
• Previous or concurrent cytotoxic chemotherapy for prostate cancer
• Severe, active co-morbidity, defined as follows:
• Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
• Transmural myocardial infarction within the last 6 months
• Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
• Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
• Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol; (patients on Coumadin or other blood thinning agents are eligible for this study)
• Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients
• Patients unable to undergo an MRI with contrast

Related Conditions & MeSH terms

• Adenocarcinoma of the Prostate
• Prostatic Neoplasms
• Recurrent Prostate Cancer
• Stage I Prostate Cancer
• Stage IIA Prostate Cancer
• Stage IIB Prostate Cancer

Intervention

Radiation:
• stereotactic radiosurgery
Undergo MRI-guided focal SRS

Device:
• magnetic resonance imaging
Undergo staging MRI with contrast

Other:
• quality-of-life assessment
Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time

Procedure:
• Serum Prostate Antigen Test
Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.
• Digital Rectal Exam
Exam of rectal health. Performed every three months for up to two years throughout the study.

Behavioral:
• Expanded Prostate Cancer Index Composite
This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.

Locations

Country	Name	City	State
United States	University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Case Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with change in EPIC bowel domain score that was worse than 5 points	Number of patients with change in EPIC bowel domain score that was worse than 5 points; A rate for the worse-than-5 point change in bowel score of up to 35% of patients will be considered acceptable, with a rate =55% specified as unacceptable	Up to 1 year from start of study
Primary	Number of patients with change in EPIC urinary domain score that was worse than 2 points	Number of patients with change in EPIC urinary domain score that was worse than 2 points; A rate for the worse-than-2 point change in urinary score of up to 40% will be considered acceptable, with a rate =60% unacceptable	Up to 1 year from start of study
Secondary	PSA response	Number of patients with PSA failure. Failure occurs when the PSA is first noted to be 2 ng/mL or more than the patient's nadir value post radiation therapy completion	Up to 2 years from start of study
Secondary	Number of acute gastrointestinal (GI) grade 3+ acute adverse events, evaluated by the Cancer Therapy Evaluation Program (CTEP) active version of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)	Defined as the first occurrence of worst severity of the adverse event =< 30 days after the completion of radiation therapy. Multivariate analysis will be used, and acute rates of GI toxicity will be reported with dose-volume histogram.	Up to 30 days after the completion of radiation therapy
Secondary	Number of acute genitourinary (GU) grade 3+ acute adverse events, evaluated by the CTEP version of the NCI CTCAE	Defined as the first occurrence of worst severity of the adverse event =< 30 days after the completion of radiation therapy.	Up to 2 years from start of study
Secondary	Number of late GI grade 3+ acute adverse events, evaluated by the CTEP version of the NCI CTCAE	Defined as the first occurrence of worst severity of adverse event > 180 days after radiation therapy completion. Multivariate analysis will be used, and acute rates of GI toxicity will be reported with dose-volume histogram.	Up to 2 years from start of study
Secondary	Number of late GU grade 3+ acute adverse events, evaluated by the CTEP version of the NCI CTCAE	Defined as the first occurrence of worst severity of adverse event > 180 days after radiation therapy completion.	Up to 2 years from start of study
Secondary	Number of patients with Disease-free survival	Defined as From the date of treatment to the date of documentation of disease progression or until the date of death from any cause. Radiographic efficacy will be summarized by calculating Kaplan-Meier curves. Also, 95% confidence intervals will be reported. Descriptive reports of Response Evaluation Criteria in Solid Tumors (RECIST) (1.1) and volumetric findings will be provided.	Up to 2 years from start of study
Secondary	Time to local progression	Radiographic efficacy will be summarized by calculating Kaplan-Meier curves. Descriptive reports of RECIST (1.1) and volumetric findings will be provided. Time will be reported in months.	Up to 2 years from start of study
Secondary	Time to distant failure	Radiographic efficacy will be summarized by calculating Kaplan-Meier curves. Descriptive reports of RECIST (1.1) and volumetric findings will be provided. Time will be reported in months.	Up to 2 years from start of study